Good afternoon, HealthTech insiders. A breakthrough device can clear the FDA and still face a long wait for Medicare coverage. CMS’s proposed RAPID pathway aims to shorten that gap. With public comments now closed, attention turns to how the agency will put the proposal into practice.
AstraZeneca, meanwhile, is committing $40 million upfront to an insitro partnership aimed at finding new medicines for liver and heart disease. And at Penn, researchers have tested a conversational AI interface that lets patients ask questions about their epilepsy-monitoring data and report what they’re experiencing.
Today’s issue follows three efforts to change how medical innovation is developed, funded and used, and examines what each still needs to prove. Let’s get into it.
In today's Signal:
RAPID’s proposed coverage route. What the 60- and 90-day goals mean, and which devices could qualify.
AI drug discovery: What AstraZeneca’s insitro partnership buys, and what its potential milestones depend on.
Patient–device communication: What Penn’s 13-person hospital study tested, and where the evidence stops.
In partnership with
Nobody's coming to approve your idea
People assume that real businesses get built by other people with more resources. It's how great ideas get stuck in notes apps and conversations.
But you don't need six months and a developer's salary to validate your concept. You just need a weekend. Describe what you want to exist and Lovable builds it: a real site, a real product, ready to accept real payments from real customers. Not a mockup to show people. An actual thing they can use.
You don't need anyone's sign-off to get started. Take $5 off your first month.
Discount of $5 applies to first month of any paid plan. You need to sign up via this webpage in order to claim the discount. The discount applies to new and returning users without an active paid plan. Terms apply.
LATEST DEVELOPMENTS
NEURAL HARDWARE & WEARABLES
1. RAPID’s Comment Window Closes: What the Proposed Coverage Route Would Change
FDA’s White Oak campus in Maryland. The proposed RAPID pathway would coordinate device development and Medicare coverage review.
With comments on CMS’s RAPID proposal due October 13, attention now turns to the agency’s response and final procedural notice. The pathway was announced in April and detailed in August. Its ambition is to coordinate device development and coverage evidence early enough to shorten the wait after FDA authorization.
The details:
The timing is a goal, not a guarantee. For qualifying devices with sufficient evidence, the proposal describes a proposed NCD alongside FDA authorization, followed by a final NCD roughly 60 days later for Class II devices or 90 days for Class III devices.
Eligibility is narrow. It covers specified Breakthrough devices at IDE pre-submission, including certain Class II TAP devices and eligible Class III PMA candidates. The proposal also includes benefit-category and separate-payability conditions; IVDs are excluded.
Evidence still matters. The planned study must address Medicare beneficiaries and relevant health outcomes. Additional evidence development may still be needed; a coverage decision should not be treated as automatic paid utilization.
The Signal: The useful shift is earlier planning. Device teams should work through the evidence and coverage questions while the study can still be shaped, and keep coding, payment and provider adoption visible as separate milestones.
AI DRUG DISCOVERY
2. AstraZeneca and insitro Strike AI Drug-Discovery Deal With $40M Upfront
Inside AstraZeneca’s Discovery Centre in Cambridge, UK. Its insitro collaboration targets new medicines for MASH and cardiomyopathies.
AstraZeneca and insitro announced an exclusive research collaboration on October 15 targeting metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies. The deal pairs insitro’s AI-enabled discovery platform with AstraZeneca’s development and commercial capabilities.
The details:
The committed payment is $40M upfront. Approximately $1.46B in additional milestones is contingent on future progress; potential single-digit royalties are separate.
The work starts before the clinic. insitro will apply its Virtual Human platform and advance AstraZeneca-nominated targets toward development candidates.
AstraZeneca owns the next stages. It will lead clinical development, regulatory activities and commercialization. No successful medicine or shorter development timeline has yet been demonstrated by this agreement.
The Signal: The meaningful commitment is the upfront payment and division of work. The larger headline value depends on candidates making it through a development process that still carries scientific and clinical risk.
CONNECTED CARE
3. Penn Tests AI That Lets Patients Communicate With Epilepsy Monitors
A patient uses a smartphone beside a hospital bed. Penn researchers tested a conversational interface linking patient questions and symptom reports with epilepsy-monitoring data.
A Nature Medicine study published October 13 explored a more interactive relationship between patients and monitoring technology. Thirteen adults undergoing inpatient epilepsy monitoring at Penn used a smartphone interface connected to EEG analytics, with an AI conversation layer for questions, alerts and symptom reports.
The details:
This was a hospital feasibility study. The single-center observational study did not change standard-of-care treatment or establish effectiveness for home use.
The live detector stayed fixed. Only the validated baseline seizure detector was deployed during patient sessions. Model fine-tuning was evaluated separately through sequential replay of data.
The false-alarm finding needs that context. The separate fine-tuning comparison reported a median 77.8% reduction in false alarms per hour across patients. That is not evidence of fewer clinical seizures or improved long-term outcomes.
The Signal: Patient feedback could become useful input for medical monitoring. This study supports further testing of that interaction; it does not yet establish a self-improving home-care device or autonomous treatment system.
QUICK HITS
👀 WHAT WE'RE WATCHING NEXT
RAPID finalization: CMS’s response to comments, any revised criteria and the effective date. The reviewed material establishes the proposal, not a fresh final notice.
Monday’s FDA deadline: Feedback on October 19, followed by clearly identified next steps; no specific 2027 guidance date has been established here.
From discovery to candidates: Watch for disclosed targets, nominated development candidates and subsequent clinical evidence from the AstraZeneca–insitro collaboration. The agreement itself does not establish those outcomes.
💰 FOLLOW THE MONEY
The deals:
Estuary Biotherapeutics: $93M Series A (October 16). Led by RA Capital Management to advance kidney-directed gene therapies. The company launched with $103M in total committed financing, including its earlier $10M seed; those are not two additional rounds. Company release.
Sirona Medical: $40M Series D (October 15). Led by Avidity Partners, with proceeds supporting its radiology platform and commercial plans. Company announcement.
Soufflé Therapeutics: $135M Series B (October 13). Led by Juvia Group to support clinical studies and further pipeline development for targeted RNA therapies. Company announcement.
The pattern: Capital is supporting kidney-directed gene therapies, radiology workflow and targeted RNA medicines. Separately, AstraZeneca’s $40M upfront insitro payment is a collaboration payment, not an equity round, and is excluded from the $268M total.
📆 UPCOMING HEALTHTECH EVENTS
DTD2026 (October 26–27, Novotel München Messe, Munich): Digital transformation and medical technology. Dr. Dereck Mush speaks on October 27 about the gap between regulatory approval and adoption.
HLTH USA (November 15–18, The Venetian Expo, Las Vegas): Healthcare innovation, care delivery, technology and investment.
RSNA 2026 (November 29–December 3, Chicago): Radiology research, education, imaging technology and AI.
🛠️ Trending HealthTech AI Tools
Virtual Human · insitro: The company’s discovery platform combines human data and machine learning to investigate disease biology. Its role in the AstraZeneca partnership is upstream drug discovery, not clinical diagnosis.
Penn conversational EEG prototype: A research-stage interface linking EEG analytics, patient reports and an AI conversation layer. Studied in 13 hospitalized adults; no routine commercial availability or home-use validation established.
RadOS · Sirona Medical: A cloud radiology platform bringing imaging, reporting and workflow capabilities together. The company announced a $40M Series D on October 15.
🛠️ Trending HealthTech AI Startups
insitro: AI-enabled drug discovery company founded and led by Daphne Koller. Its new AstraZeneca agreement covers MASH and cardiomyopathies; the $40M upfront is collaboration revenue, not a new funding round.
Sirona Medical: Cloud radiology software company developing RadOS; $40M Series D led by Avidity Partners announced October 15.
Limbic: Mental health AI company whose Unpacked product is listed for a specified intended use in FDA’s TEMPO pilot. Selection does not establish effectiveness for that use; no new financing is claimed here.
DECISION INTELLIGENCE
Highlights: Deep Dives & Industry Reports
Where would stronger evidence make the biggest difference?
That's it for today!
A proposed coverage route, a discovery partnership and a bedside research prototype all sit at different points on the path into care. RAPID needs a workable final process. insitro and AstraZeneca need viable drug candidates. Penn’s interface needs broader testing beyond a small inpatient study.
The next useful signal is what each approach can demonstrate at its next stage: a clearer route to coverage, stronger biological evidence or a monitoring system patients and clinicians can use reliably.
How did we do today?
See you tomorrow,
Dr. Dereck Mush, MD, MBA
The HealthTech Signal is independently funded. Sponsorships help us invest in better reporting, research, and a stronger newsletter for our readers. Want to reach HealthTech founders & executives while supporting the Signal? Get in touch.
Was this email forwarded to you? Sign up here.
Until tomorrow,
The HealthTech Signal